- Report
- March 2025
- 175 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- May 2024
- 131 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Report
- May 2024
- 128 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Report
- February 2021
- 420 Pages
United States
From €2047EUR$2,160USD£1,710GBP
€2275EUR$2,400USD£1,900GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1185EUR$1,250USD£990GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
- Book
- February 2024
- 592 Pages
Vilazodone is a prescription medication used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD). It is a serotonin partial agonist and reuptake inhibitor (SPARI) that works by increasing the amount of serotonin in the brain. Vilazodone is a relatively new drug, having been approved by the U.S. Food and Drug Administration (FDA) in 2011. It is available in both immediate-release and extended-release formulations.
Vilazodone is used as an adjunct to other treatments for mental disorders, such as psychotherapy and lifestyle changes. It is generally well-tolerated, with the most common side effects being nausea, headache, and insomnia. It is not recommended for use in children or adolescents.
The market for mental disorder drugs is highly competitive, with many different companies offering various medications. Some of the major players in the vilazodone market include Allergan, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more